Zydus Lifesciences receives final approval from USFDA for Famotidine Tablets

Ahmedabad, India, 06 June, 2022

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Tablets in the strengths of 20mg and 40mg (USRLD: Pepcid). Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach (acid indigestion). The drug will be manufactured at group's drug formulation facility at SEZ, Ahmedabad. Famotidine Tablet has a market size of USD 67 mn (as per IQVIA MAT April 2022).

The group now has 315 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com.

*(*As per the Q4 FY22 investor presentation issued on 20th May, 2022)*

****

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878